Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in Huddinge – page 46

745 clinical trials in Huddinge, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Huddinge at a glance
745
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

745 trials in Huddinge

Open in trial search

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Ovarian cancer

Not recruiting

Study of olaparib, durvalumab and UV1 combination as maintenance treatment for patients with recurrent ovarian cancer who do not have BRCA mutations

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Nordic Society Of Gynaecological Oncology Clinical Trial Unit

Colorectal cancer

Not recruiting

Study of organ preservation using chemoradiotherapy and transanal surgery compared to standard surgery in patients with early rectal cancer (STAR-TREC trial)

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:The University Of Birmingham

EGFR gene mutation+1

Not recruiting

Study of Osimertinib for Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:Vestre Viken HF

Neoplasm malignant

Not recruiting

Study of Nivolumab and Entinostat for Children and Adolescents with High-Risk Refractory or Relapsed Malignant Disease

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Entinostat
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Hormone-dependent prostate cancer

Not recruiting

Study Comparing 177Lu-PSMA-617 with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Novartis Pharma AG

Dermatitis atopic

Not recruiting

Study on Tralokinumab for Moderate-to-Severe Atopic Hand Eczema in Patients Needing Systemic Therapy

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Tralokinumab
  • Sponsor:LEO PHARMA A/S

Hormone-refractory prostate cancer

Not recruiting

Study on Lutetium (177Lu) Vipivotide Tetraxetan for Men with Progressive Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Novartis Pharma AG

Haemophilia B with anti factor IX+1

Not recruiting

Study on How Concizumab Works for Patients with Hemophilia A or B with Inhibitors

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Concizumab
  • Sponsor:Novo Nordisk A/S

Bladder cancer

Not recruiting

Study of Pembrolizumab and Enfortumab Vedotin with Surgery vs. Surgery Alone for Patients with Muscle-Invasive Bladder Cancer Who Cannot or Choose Not to Use Cisplatin

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Hypertriglyceridaemia

Not recruiting

Study on the Safety of A24110He for Patients with Type 2 Diabetes and High Triglycerides

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Lipigon Pharmaceuticals AB

Prophylaxis against transplant rejection

Not recruiting

Study on Siplizumab and Rabbit Anti-Thymocyte Globulin for Preventing Rejection in New Kidney Transplant Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Paracetamol
  • Sponsor:Itb-Med AB

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Huddinge

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies exploring treatments for heart failure prevention and cardiovascular disease, including investigations into cholesterol metabolism and blood pressure management.

  • PCSK9 inhibitors and statins research
  • Heart failure prevention trials
  • Lipoprotein management studies

Comprehensive research focusing on reducing cardiovascular events and improving patient outcomes.

02 Oncology Studies

Groundbreaking research in blood cancers, including acute myeloid leukemia and multiple myeloma, with innovative therapeutic approaches.

  • Advanced breast cancer treatments
  • Leukemia therapy combinations
  • CAR T Cell therapy trials

Studies evaluating novel treatment combinations and targeted therapies for various cancer types.

03 Neurological Disorders

Clinical investigations focusing on Alzheimer's disease and amyotrophic lateral sclerosis, exploring innovative therapeutic approaches.

  • Cognitive impairment treatments
  • ALS survival studies
  • Inflammatory response research

Studies examining new therapeutic options for progressive neurological conditions.

04 Chronic Conditions

Research initiatives addressing chronic kidney disease, cystic fibrosis, and other long-term health conditions.

  • Kidney disease management
  • Diabetes treatment studies
  • Organ transplant research

Comprehensive studies aimed at improving quality of life for patients with chronic conditions.

Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.